Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.

  PMID 41748546 · PMC13004963 · Cell death & disease · 2026 · 7 claims · 8 setups

  Full-text index only

  A shared PI3K/AKT-regulated signaling node governs drug adaptation across all long-term resistant (lt-res) ADA and PTX models

  hgsoc kuramochi jhos2 parental long-term inducible overexpression

• Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression.

  PMID 16083501 · PMC1208945 · Molecular cancer · 2005 · 8 claims · 8 setups

  Full-text index only

  Restoration of TSLC1 expression in A549 cells (yielding the 12.2 line) suppresses tumorigenic growth, markedly reducing cell expansion/proliferation rate.

  a549 nsclc expansion wst-1 flow

• NELF prevents transcriptional readthrough into DNA replication zones in cancer cells.

  PMID 41721097 · PMC13076867 · EMBO reports · 2026 · 8 claims · 8 setups

  Full-text index only

  NELFCD transcript and NELF subunit protein levels are significantly upregulated in colorectal tumors (COAD/READ) relative to normal tissue

  gtex nelf-c-aid spt4-aid parental rna-seq western growth

• The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations.

  PMID 41735640 · PMC13035475 · Nature cancer · 2026 · 8 claims · 8 setups

  Full-text index only

  GENEVA is a scalable single-cell-resolution platform for measuring drug responses across genetically diverse pooled 2D/3D cultures and xenograft models

  pooled pool nsg mosaic scrna-seq crispri mitotracker